Shareholder rights advocates at levi & korsinsky investigate agenus inc. (agen) regarding possible securities fraud violations

New york, ny / accesswire / july 23, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of agenus inc. ("agenus") (nasdaq:agen) concerning possible violations of federal securities laws. agenus issued a press release on july 18, 2024, "announc[ing] the results of its end-of-phase 2 (eop2) meeting with the u.s. food and drug administration (fda), for the advancement of its immunotherapy combination, botensilimab (bot) and balstilimab (bal), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r mss crc) with no active liver metastases (nlm).
AGEN Ratings Summary
AGEN Quant Ranking